DÄ internationalArchiveReferences
References

Review article

Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes

Dtsch Arztebl Int 2019; 116: 747-54. DOI: 10.3238/arztebl.2019.0747

Buchert, R; Buhmann, C; Apostolova, I; Meyer, P T; Gallinat, J

1.DGN, AWMF: S3-Leitlinie „Idiopathisches Parkinson-Syndrom“. AWMF-Register-Nummer: 030–010. 2016. www.awmf.org/uploads/tx_szleitlinien/030–010l_S3_Parkinson_Syndrome_Idiopathisch_2016–06.pdf (last accessed on 3 September 2019).
2.Postuma RB, Berg D, Stern M, et al.: MDS clinical diagnostic criteria for Parkinson‘s disease. Mov Disord 2015; 30: 1591–601 CrossRef MEDLINE
3.Gilman S, Wenning GK, Low PA, et al.: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–6 CrossRef MEDLINE PubMed Central
4.Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G: Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 2016; 86: 566–76 CrossRef MEDLINE
5.Meyer PT, Frings L, Hellwig S: Nuklearmedizinische Differenzialdiagnostik der Parkinson-Syndrome: Update 2016. Der Nuklearmediziner 2016; 39: 245–58 CrossRef
6.Neumeyer JL, Wang SY, Gao YG, et al.: N-Omega-Fluoroalkyl Analogs of
(1r)-2-Beta-Carbomethoxy-3-Beta-(4-Iodophenyl)-Tropane (Beta-Cit) – radiotracers for positron emission tomography and single-photon emission computed-tomography imaging of dopamine transporters. J Med Chem 1994; 37: 1558–61 CrossRef MEDLINE
7.Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W: Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014; 29: 1767–73 CrossRef MEDLINE
8.Colloby SJ, McParland S, O‘Brien JT, Attems J: Neuropathological correlates of dopaminergic imaging in Alzheimer‘s disease and Lewy body dementias. Brain 2012; 135: 2798–808 CrossRef MEDLINE
9.Perju-Dumbrava LD, Kovacs GG, Pirker S, et al.: Dopamine transporter imaging in autopsy-confirmed parkinson‘s disease and multiple system atrophy. Movement Disord 2012; 27: 65–71 CrossRef MEDLINE
10.Booij J, Dubroff J, Pryma D, et al.: Diagnostic performance of the visual reading of (123)I-Ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. J Nucl Med 2017; 58: 1821–6 CrossRef MEDLINE
11.Seibyl JP, Kupsch A, Booij J, et al.: Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. J Nucl Med 2014; 55: 1288–96 CrossRef MEDLINE
12.Albert NL, Unterrainer M, Diemling M, et al.: Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging 2016; 43: 1315–22 CrossRef MEDLINE
13.Lee I, Kim JS, Park JY, et al.: Head-to-head comparison of (18)F-FP-CIT and (123) I-FP-CIT for dopamine transporter imaging in patients with Parkinson‘s disease: a preliminary study. Synapse 2018; 72: e22032 CrossRef MEDLINE
14.Kordower JH, Olanow CW, Dodiya HB, et al.: Disease duration and the integrity of the nigrostriatal system in Parkinson‘s disease. Brain 2013; 136: 2419–31 CrossRef MEDLINE PubMed Central
15.Marshall VL, Reininger CB, Marquardt M, et al.: Parkinson‘s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24: 500–8 CrossRef MEDLINE
16.Pirker W, Djamshidian S, Asenbaum S, et al.: Progression of dopaminergic degeneration in Parkinson‘s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17: 45–53 CrossRef MEDLINE
17.Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM: The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson‘s disease or clinically uncertain parkinsonism: a systematic review. Ejnmmi Res 2015; 5: 12 CrossRef MEDLINE PubMed Central
18.Marek KL, Jennings DL, Seibyl JP, Grp PS: Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005;64(suppl 1): Abstract 274.
19.Batla A, Erro R, Stamelou M, et al.: Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord 2014; 29: 1820–5 CrossRef MEDLINE
20.Hickey PT, Kuchibhatla M, Scott B, Gauger L, Stacy MA: Dopamine transporter imaging has no impact on functional outcomes in de novo probable Parkinson‘s disease. J Parkinson Dis 2017; 7: 279–87 CrossRef MEDLINE
21.Berardelli A, Wenning GK, Antonini A, et al.: EFNS/MDS-ES recommendations for the diagnosis of Parkinson‘s disease. Eur J Neurol 2013; 20: 16–34 CrossRef MEDLINE
22.NICE: Parkinson’s disease in adults. National Institute for Health and Care Excellence (NICE) guideline [NG71], 2017. www.nice.org.uk/guidance/ng71 (last accessed on 3 September 2019).
23.Catafau AM, Tolosa E, Da TCUPSSG: Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19: 1175–82 CrossRef MEDLINE
24.Booij J, Speelman JD, Horstink MW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266–72 CrossRef MEDLINE
25.Hellwig D, Marienhagen J, Menhart K, Grosse J: [Nuclear medicine in Germany. Updated key data and trends from official statistics]. Nuklearmedizin 2017; 56: 55–68 CrossRef MEDLINE
26.Van Laere K, Everaert L, Annemans L, Gonce M, Vandenberghe W, Vander Borght T: The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35: 1367–76 CrossRef MEDLINE
27.Kupsch AR, Bajaj N, Weiland F, et al.: Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosur Ps 2012; 83: 620–8 CrossRef MEDLINE
28.Grosset DG, Tatsch K, Oertel WH, et al.: Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan). J Nucl Med 2014; 55: 1281–7 CrossRef MEDLINE
29.Booij J, Sokole EB, Stabin MG, Janssen AGM, de Bruin K, van Royen EA: Human biodistribution and dosimetry of [I-123]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998; 25: 24–30 CrossRef
30.Booij J, Kemp P: Dopamine transporter imaging with [I-123]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol I 2008; 35: 424–38 CrossRef MEDLINE
31.Tatsch K, Buchert R, Bartenstein P, et al.: Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM). Nuklearmedizin 2019; 58: 5–16 CrossRef MEDLINE
32.Meyer PT, Frings L, Rucker G, Hellwig S: (18)F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 2017; 58: 1888–98 CrossRef MEDLINE
33.Eckert T, Barnes A, Dhawan V, et al.: FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912–21 CrossRef MEDLINE
34.Hellwig S, Amtage F, Kreft A, et al.: [18F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79: 1314–22 CrossRef MEDLINE
35.Niethammer M, Tang CC, Feigin A, et al.: A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 2014; 137: 3036–46 CrossRef MEDLINE PubMed Central
36.Pilotto A, Premi E, Caminiti SP, et al.: Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology 2018; 90: E1029–E37 CrossRef MEDLINE
37.Hellwig S, Frings L, Amtage F, et al.: 18F-FDG PET Is an early predictor of overall survival in suspected atypical parkinsonism. J Nucl Med 2015; 56: 1541–6 CrossRef MEDLINE
38.Walker Z, Gandolfo F, Orini S, et al.: Clinical utility of FDG PET in Parkinson‘s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging 2018; 45: 1534–45 CrossRef MEDLINE PubMed Central
39.Whitwell JL, Hoglinger GU, Antonini A, et al.: Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017; 32: 955–71 CrossRef MEDLINE PubMed Central
40.Buchert R, Lange C, Apostolova I, Meyer PT: Dopamintransporter-SPECT mit [123I]FP-CIT: Empfehlungen für die visuelle Beurteilung. Der Nuklearmediziner 2015; 38: 40–7 CrossRef
e1.Hoglinger GU, Respondek G, Stamelou M, et al.: Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society Criteria. Movement Disord 2017; 32: 853–64 CrossRef MEDLINE PubMed Central
e2.Armstrong MJ, Litvan I, Lang AE, et al.: Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496–503 CrossRef MEDLINE PubMed Central
e3.Grosset D, Taurah L, Burn DJ, et al.: A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson‘s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007; 78: 465–9 CrossRef MEDLINE PubMed Central
e4.Diaz NL, Waters CH: Current strategies in the treatment of Parkinson‘s disease and a personalized approach to management. Expert Rev Neurother 2009; 9: 1781–9 CrossRef MEDLINE
e5.Global Parkinson‘s Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson‘s disease: results from an international survey. Mov Disord 2002; 17: 60–7 CrossRef MEDLINE
e6.Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU: The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int 2016; 113: 61–9 CrossRef MEDLINE PubMed Central
e7.Koga S, Aoki N, Uitti RJ, et al.: When DLB, PD, and PSP masquerade as MSA. An autopsy study of 134 patients. Neurology 2015; 85: 404–12 CrossRef MEDLINE PubMed Central
e8.Koga S, Kouri N, Walton RL, et al.: Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica 2018; 136: 389–404 CrossRef MEDLINE PubMed Central
e9.Knudsen K, Borghammer P: Imaging the Autonomic Nervous System in Parkinson‘s Disease. Curr Neurol Neurosci Rep 2018; 18: 79 CrossRef MEDLINE
e10.Dickson DW: Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 Suppl 2: II6–15 CrossRef MEDLINE
e11.Dickson DW, Bergeron C, Chin SS, et al.: Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935–46 CrossRef MEDLINE
e12.Piggott MA, Marshall EF, Thomas N, et al.: Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer‘s and Parkinson‘s diseases: rostrocaudal distribution. Brain 1999; 122 (Pt 8): 1449–68 CrossRef MEDLINE
e13.Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP: Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58: 160–6 CrossRef MEDLINE PubMed Central
e14.Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415–55 CrossRef
e15.Niznik HB, Fogel EF, Fassos FF, Seeman P: The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56: 192–8 CrossRef MEDLINE
e16.Fazio P, Svenningsson P, Cselenyi Z, Halldin C, Farde L, Varrone A: Nigrostriatal dopamine transporter availability in early Parkinson‘s disease. Mov Disord 2018; 33: 592–9 CrossRef MEDLINE
e17.Lee CS, Samii A, Sossi V, et al.: In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson‘s disease. Ann Neurol 2000; 47: 493–503 CrossRef
e18.Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V: Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 2017; 88: 1461–7 CrossRef MEDLINE
e19.Honkanen EA, Saari L, Orte K, et al.: No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson‘s disease. Mov Disord 2019; doi: 10.1002/mds.27777. [Epub ahead of print] CrossRef MEDLINE
e20.Seibyl JP, Marek K, Sheff K, et al.: Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson‘s patients. J Nucl Med 1998; 39: 1500–8.
e21.Van Laere K, De Ceuninck L, Dom R, et al.: Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004; 31: 1119–27 CrossRef MEDLINE
e22.Kim HJ, Im JH, Yang SO, et al.: Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson‘s disease subjects. J Nucl Med 1997; 38: 1703–11.
e23.Fischman AJ, Bonab AA, Babich JW, et al.: Rapid detection of Parkinson‘s disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998; 29: 128–41 CrossRef
e24.Ziebell M: Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT. Dan Med Bull 2011; 58: B4279.
e25.Andringa G, Drukarch B, Bol JG, et al.: Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson‘s disease. Neuroimage 2005; 26: 1150–8 CrossRef MEDLINE
e26.Alvarez-Fischer D, Blessmann G, Trosowski C, et al.: Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson‘s disease. Neuroimage 2007; 38: 5–12 CrossRef MEDLINE
e27.Back S, Raki M, Tuominen RK, Raasmaja A, Bergstrom K, Mannisto PT: High correlation between in vivo [123I]beta-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. Ejnmmi Res 2013; 3: 46 CrossRef MEDLINE PubMed Central
e28.Gleave JA, Farncombe TH, Saab C, Doering LC: Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson‘s. Nucl Med Biol 2011; 38: 741–9 CrossRef MEDLINE
e29.Ashkan K, Wallace BA, Mitrofanis J, et al.: SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson‘s disease. Parkinsonism Relat Disord 2007; 13: 266–75 CrossRef MEDLINE
e30.Tian L, Karimi M, Brown CA, Loftin SK, Perlmutter JS: In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. Brain Res 2014; 1571: 49–60 CrossRef MEDLINE PubMed Central
e31.Karimi M, Tian L, Brown CA, et al.: Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013; 73: 390–6 CrossRef MEDLINE PubMed Central
e32.Papathanasiou N, Rondogianni P, Chroni P, et al.: Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies. Ann Nucl Med 2012; 26: 234–40 CrossRef MEDLINE
e33.Ahmed A, Huang JB, Chen K, Zubeldia JM, Booij J, Vijayakumar V: [I-123]Ioflupane imaging in Caucasians and non-Caucasians: are there any differences? J Neurol Sci 2018; 395: 159–63 CrossRef MEDLINE
e34.Makinen E, Joutsa J, Johansson J, Maki M, Seppanen M, Kaasinen V: Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism. J Neural Transm (Vienna) 2016; 123: 1309–18 CrossRef MEDLINE
e35.Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL: Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson‘s disease and healthy controls. Eur J Nucl Med Mol Imaging 2009; 36: 454–62 CrossRef MEDLINE
e36.Jakobson Mo S, Axelsson J, Jonasson L, et al.: Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT-a clinical comparison. Ejnmmi Res 2018; 8: 100 CrossRef MEDLINE PubMed Central
e37.Marek K, Seibyl J, Eberly S, et al.: Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82: 1791–7 CrossRef MEDLINE PubMed Central
e38.Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA: Time trends in the incidence of Parkinson disease. JAMA Neurol 2016; 73: 981–9 CrossRef MEDLINE PubMed Central
e39.Oravivattanakul S, Benchaya L, Wu G, et al.: Dopamine Transporter (DaT) Scan utilization in a movement disorder center. Mov Disord Clin Pract 2016; 3: 31–5 CrossRef MEDLINE PubMed Central
e40.Vlaar AM, de Nijs T, Kessels AG, et al.: Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59: 258–66 CrossRef MEDLINE
e41.Dodel RC, Hoffken H, Moller JC, et al.: Dopamine transporter imaging and SPECT in diagnostic workup of Parkinson‘s disease: a decision-analytic approach. Movement Disord 2003; 18: S52–S62 CrossRef MEDLINE
e42.Bruggenjurgen B, Smala A, Chambers M: Cost-effectiveness of non-invasive imaging in the diagnosis of Parkinsonism. Value Health 2005; 8: Aabstract 15 CrossRef
e43.Busca R, Antonini A, Lopatriello S, Berto P: Economic evaluation of SPECT-DaTSCAN in the diagnosis of patients with clinically uncertain Parkinsonism in Italy. Value Health 2005; 8: Abstract 14 CrossRef
e44.Rajput AH, Rozdilsky B, Rajput A: Accuracy of clinical diagnosis in parkinsonism—a prospective study. Can J Neurol Sci 1991; 18: 275–8 CrossRef MEDLINE
e45.Iranzo A, Santamaria J, Valldeoriola F, et al.: Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 2017; 82: 419–28 CrossRef MEDLINE
e46.Postuma RB, Iranzo A, Hu M, et al.: Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019; 142: 744–59 CrossRef MEDLINE PubMed Central
e47.Chahine LM, Iranzo A, Fernandez-Arcos A, et al.: Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. NPJ Parkinsons Dis 2019; 5: 2 CrossRef MEDLINE PubMed Central
e48.Meles SK, Vadasz D, Renken RJ, et al.: FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. Mov Disord 2017; 32: 1482–6 CrossRef MEDLINE PubMed Central
e49.Geisler S, Beindorff N, Cremer M, et al.: Characterization of [I-123]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative in vitro autoradiography. Synapse 2015; 69: 497–504 CrossRef MEDLINE
e50.Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J: [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28: 561–72 CrossRef
e51.Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Verfahren. Salzgitter: Bundesamt für Strahlenschutz 2012. www.bfs.de/DE/themen/ion/anwendung-medizin/diagnostik/referenzwerte/referenzwerte_node.html (last accessed on 3 September 2019.)
e52.Coon EA, Sletten DM, Suarez MD, et al.: Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 2015; 138: 3623–31 CrossRef MEDLINE PubMed Central
e53.Wenning GK, Litvan I, Jankovic J, et al.: Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184–9 CrossRef MEDLINE PubMed Central
e54.Brigo F, Matinella A, Erro R, Tinazzi M: [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson‘s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 2014; 21: 1369–e90 CrossRef MEDLINE
e55.Thomsen G, Knudsen GM, Jensen PS, et al.: No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res 2013; 3: 39 CrossRef MEDLINE PubMed Central
e56.Kaasinen V, Gardberg M, Roytta M, Seppanen M, Paivarinta M: Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration. J Neurol 2013; 260: 1410–1 CrossRef MEDLINE
e57.O‘Sullivan SS, Burn DJ, Holton JL, Lees AJ: Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. Mov Disord 2008; 23: 2424–6 CrossRef MEDLINE
e58.Ceravolo R, Rossi C, Cilia R, et al.: Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. Parkinsonism Relat Disord 2013; 19: 557–9 CrossRef MEDLINE
e59.Tissot H, Frismand S, Marie PY, Gospodaru N, Verger A: 123I-FP-CIT-SPECT in encephalitis involving substantia nigra. Clin Nucl Med 2016; 41: e445–6 CrossRef MEDLINE
e60.Peña E, Fernandez C: Abnormal DAT SCAN in a patient with parkinsonism after a midbrain ischemic lesion. Mov Disord 2012; 27: 205 CrossRef MEDLINE
e61.Kaasinen V, Kankare T, Joutsa J, Vahlberg T: Presynaptic striatal dopaminergic function in atypical parkinsonisms: a meta-analysis of imaging studies. J Nucl Med 2019; pii: jnumed.119.227140. doi: 10.2967/jnumed.119.227140. [Epub ahead of print] CrossRef MEDLINE
e62.Kadekaro M, Crane AM, Sokoloff L: Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci USA 1985; 82: 6010–3 CrossRef MEDLINE PubMed Central
e63.Sokoloff L: Energetics of functional activation in neural tissues. Neurochem Res 1999; 24: 321–9 CrossRef MEDLINE
e64.Harris JJ, Jolivet R, Attwell D: Synaptic energy use and supply. Neuron 2012; 75: 762–77 CrossRef MEDLINE
e65.Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE: A diagnostic approach in Alzheimer‘s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238–48.
e66.Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith C, Frackowiak RSJ: Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2: 189–210 CrossRef
e67.Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE: Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996; 198: 837–43 CrossRef MEDLINE
e68.Hoglinger GU: Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No. Mov Disord Clin Prac 2018; 5: 141–4 CrossRef MEDLINE PubMed Central
e69.Hoglinger GU, Respondek G, Kovacs GG: New classification of tauopathies. Rev Neurol (Paris) 2018; 174: 664–8 CrossRef MEDLINE
e70.Ling H, Macerollo A: Is it useful to classify PSP and CBD as different disorders? Yes. Mov Disord Clin Prac 2018; 5: 145–8 CrossRef MEDLINE PubMed Central
e71.Hoglinger GU, Kassubek J, Csoti I, et al.: Differentiation of atypical Parkinson syndromes. J Neural Transm 2017; 124: 997–1004 CrossRef MEDLINE
e72.Bohnen NI, Koeppe RA, Minoshima S, et al.: Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848–55 CrossRef MEDLINE
e73.Zalewski N, Botha H, Whitwell JL, Lowe V, Dickson DW, Josephs KA: FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol 2014; 261: 710–6 CrossRef MEDLINE
e74.Cordato NJ, Halliday GM, McCann H, et al.: Corticobasal syndrome with tau pathology. Mov Disord 2001; 16: 656–67 CrossRef MEDLINE
e75.Josephs KA, Duffy JR, Strand EA, et al.: Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129: 1385–98 CrossRef MEDLINE PubMed Central
e76.Klein RC, de Jong BM, de Vries JJ, Leenders KL: Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson‘s disease. Mov Disord 2005; 20: 1021–30 CrossRef MEDLINE
e77.Tetzloff KA, Duffy JR, Strand EA, et al.: Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase 2018; 24: 111–20 CrossRef MEDLINE PubMed Central
e78.Kaasinen V: Ipsilateral deficits of dopaminergic neurotransmission in Parkinson‘s disease. Ann Clin Transl Neurol 2016; 3: 21–6 CrossRef MEDLINE PubMed Central
e79.Kaasinen V, Vahlberg T: Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol 2017; 82: 873–82 CrossRef MEDLINE
e80.Apostolova I, Taleb DS, Lipp A, et al.: Utility of follow-up dopamine transporter SPECT with 123I-FP-CIT in the diagnostic workup of patients with clinically uncertain parkinsonian syndrome. Clin Nucl Med 2017; 42: 589–94 CrossRef MEDLINE
e81.Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD: Differentiating multiple system atrophy from Parkinson‘s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosur Ps 2002; 73: 517–23 CrossRef MEDLINE PubMed Central
e82.Armstrong MJ, Weintraub D: The case for antipsychotics in dementia with Lewy bodies. Mov Disord Clin Pract 2017; 4: 32–5 CrossRef MEDLINE PubMed Central
e83.Fujimi K, Sasaki K, Noda K, et al.: Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: The hisayama study. Brain Pathol 2008; 18: 317–25 CrossRef PubMed Central
e84.Hogan DB, Fiest KM, Roberts JI, et al.: The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci 2016; 43: S83–S95 CrossRef MEDLINE
e85.McKeith I, O‘Brien J, Walker Z, et al.: Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305–13 CrossRef
e86.Walker Z, Jaros E, Walker RW, et al.: Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007; 78: 1176–81 CrossRef MEDLINE PubMed Central
e87.McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C: Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev 2015; 1: CD010633 CrossRef
e88.Walker RW, Walker Z: Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 2009; 24 (Suppl 2): S754–9 CrossRef MEDLINE
e89.Thomas AJ, Attems J, Colloby SJ, et al.: Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 2017; 88: 276–83 CrossRef MEDLINE PubMed Central
e90.Beach TG, Adler CH, Lue L, et al.: Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117: 613–34 CrossRef MEDLINE PubMed Central
e91.van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW: [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2016; 43: 1060–6 CrossRef MEDLINE PubMed Central
e92.Jung Y, Jordan LG, 3rd, Lowe VJ, et al.: Clinicopathological and (123)I-FP-CIT SPECT correlations in patients with dementia. Ann Clin Transl Neurol 2018; 5: 376–81 CrossRef MEDLINE PubMed Central
e93.Lloyd JJ, Petrides G, Donaghy PC, et al.: A new visual rating scale for Ioflupane imaging in Lewy body disease. Neuroimage Clin 2018; 20: 823–9 CrossRef MEDLINE PubMed Central
e94.Sonni I, Ratib O, Boccardi M, et al.: Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer‘s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging 2017; 52: 228–42 CrossRef MEDLINE
e95.Morgan S, Kemp P, Booij J, et al.: Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry 2012; 83: 1063–70 CrossRef MEDLINE
e96.McKeith IG, Boeve BF, Dickson DW, et al.: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88–100 CrossRef MEDLINE PubMed Central
e97.Ba F, Martin WR: Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord 2015; 21: 87–94 CrossRef MEDLINE
e98.Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE: Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7: 27 CrossRef MEDLINE PubMed Central
e99.O‘Brien JT, Oertel WH, McKeith IG, et al.: Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open 2014; 4: e005122 CrossRef MEDLINE PubMed Central
e100.Parkinson Study Group: A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55: 1540–7 CrossRef MEDLINE
e101.Benamer TS, Patterson J, Grosset DG, et al.: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15: 503–10 CrossRef
e102.Weng YH, Yen TC, Chen MC, et al.: Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson‘s disease from healthy subjects. J Nucl Med 2004; 45: 393–401.
e103.Jakobson Mo S, Linder J, Forsgren L, Riklund K: Accuracy of visual assessment of dopamine transporter imaging in early Parkinsonism. Mov Disord Clin Pract 2015; 2: 17–23 CrossRef MEDLINE PubMed Central
e104.Gayed I, Joseph U, Fanous M, et al.: The impact of DaTscan in the diagnosis of Parkinson disease. Clin Nucl Med 2015; 40: 390–3 CrossRef MEDLINE
e105.Werner RA, Marcus C, Sheikhbahaei S, et al.: Visual and semiquantitative accuracy in clinical baseline 123I-Ioflupane SPECT/CT imaging. Clinical Nuclear Medicine 2019; 44: 1–3 CrossRef MEDLINE
e106.Buchert R, Lange C, Spehl TS, et al.: Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting. EJNMMI Res 2019; 9: 37 CrossRef MEDLINE PubMed Central
e107.Skanjeti A, Castellano G, Elia BO, et al.: Multicenter semiquantitative evaluation of (123)I-FP-CIT brain SPECT. J Neuroimaging 2015; 25: 1023–9 CrossRef MEDLINE
e108.Bouwmans AE, Vlaar AM, Mess WH, Kessels A, Weber WE: Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson‘s disease: prospective cohort study in 196 patients. BMJ Open 2013; 3: pii: e002613 CrossRef MEDLINE PubMed Central
e109.Ziebell M, Andersen BB, Thomsen G, et al.: Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms. Eur J Nucl Med Mol Imaging 2012; 39: 242–50 CrossRef MEDLINE
e110.Felicio AC, Godeiro-Junior C, Shih MC, et al.: Evaluation of patients with clinically unclear parkinsonian syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. J Neurol Sci 2010; 291: 64–8 CrossRef MEDLINE
e111.Vlaar AM, de Nijs T, van Kroonenburgh MJ, et al.: The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol 2008; 8: 42 CrossRef MEDLINE PubMed Central
e112.Tolosa E, Borght TV, Moreno E, Uncertain DC: Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007; 22: 2346–51 CrossRef MEDLINE
e113.Plotkin M, Amthauer H, Klaffke S, et al.: Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm (Vienna) 2005; 112: 677–92 CrossRef MEDLINE
e114.Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J: How useful is [123I] beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005; 76: 1211–6 CrossRef MEDLINE PubMed Central
e115.Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K: (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61: 1224–9 CrossRef MEDLINE
e116.Lokkegaard A, Werdelin LM, Friberg L: Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002; 29: 1623–9 CrossRef MEDLINE
e117.Crotty GF, O‘Corragain OA, Bogue C, Crotty J, O‘Sullivan SS: The utility of dopamine transporter scans for diagnosing Parkinsonian disorders. Ir Med J 2018; 111: 751.
e118.Mirpour S, Turkbey EB, Marashdeh W, El Khouli R, Subramaniam RM: Impact of DAT-SPECT on management of patients suspected of Parkinsonism. Clin Nucl Med 2018; 43: 710–4 CrossRef MEDLINE
e119.Yomtoob J, Koloms K, Bega D: DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat Disord 2018; 53: 37–41 CrossRef MEDLINE
e120.Graebner AK, Tarsy D, Shih LC, et al.: Clinical impact of 123I-ioflupane SPECT (DaTscan) in a movement disorder center. Neurodegener Dis 2017; 17: 38–43 CrossRef MEDLINE
e121.Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T: Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? Neurodegener Dis 2015; 15: 81–6 CrossRef MEDLINE
e122.Covington MF, Sherman S, Lewis D, Lei H, Krupinski E, Kuo PH: Patient survey on satisfaction and impact of 123I-ioflupane dopamine transporter imaging. PLoS One 2015; 10: e0134457 CrossRef MEDLINE PubMed Central
e123.Sadasivan S, Friedman JH: Experience with DaTscan at a tertiary referral center. Parkinsonism Relat Disord 2015; 21: 42–5 CrossRef MEDLINE
e124.Thiriez C, Itti E, Fenelon G, et al.: Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J Neurol 2015; 262: 909–15 CrossRef MEDLINE